Oruka Therapeutics (ORKA) Consolidated Net Income (2010 - 2024)

Oruka Therapeutics' Consolidated Net Income history runs 15 years deep, the most recent figure standing at -$2.7 million for Q2 2024.

• In Q2 2024, Consolidated Net Income fell 80.95% year-over-year to -$2.7 million; the TTM figure through Mar 2025 stood at -$2.7 million (up 55.38% YoY), while the FY2023 annual figure was -$5.3 million, up 46.21% from the prior year.
• Consolidated Net Income was -$2.7 million for Q2 2024 at Oruka Therapeutics, down from -$2.0 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of -$1.1 million in Q4 2023 to a low of -$5.7 million in Q4 2021.
• Historically, Consolidated Net Income has averaged -$2.7 million across 5 years, with a median of -$2.2 million in 2022.
• The sharpest annual moves came in 2020 and 2022: Consolidated Net Income tumbled 318.03% in 2020, then jumped 79.32% in 2022.
• A 5-year view of Consolidated Net Income shows it stood at -$5.1 million in 2020, then fell by 10.75% to -$5.7 million in 2021, then surged by 79.32% to -$1.2 million in 2022, then increased by 7.24% to -$1.1 million in 2023, then tumbled by 145.91% to -$2.7 million in 2024.
• The last three Consolidated Net Income figures came in at -$2.7 million (Q2 2024), -$2.0 million (Q1 2024), and -$1.1 million (Q4 2023), per Business Quant data.